Type 2 DiabetesNCT02633722
Intermittent Fasting for Metabolic Health, Does Meal Timing Matter?
A study testing Lifestyle intervention B and Lifestyle Intervention D in people with Type 2 Diabetes and Insulin Resistance, run by University of Adelaide at 1 site in Australia.
Trial summary
Obesity is a serious medical condition, the adverse consequences of which include increased risk of cardiovascular disease, diabetes mellitus, reduced fertility and cancer. The economic cost of obesity was placed at $58 billion dollars in Australia in 2008. Read more about this study
- Who is it for?
- Ages 30 to 70 years, men onlyHealthy volunteers can take part
- Conditions the study is for
- Type 2 Diabetes, Insulin Resistance
- What is being tested?
- Lifestyle intervention B and Lifestyle Intervention D
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 15 participants
- Where
- 1 siteAustralia
- Study dates
- Jan 2016to 30 Jul 2018
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 30 to 70 years
- Men only
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Waist circumference >102cm
- BMI >30 kg/m2
Who cannot join
- Personal history of cardiovascular disease, diabetes, eating disorders
- use of medications which may affect energy metabolism, gastrointestinal function, body weight or appetite (e.g. domperidone and cisapride, anticholinergic drugs, androgenic medications, metoclopramide, orlistat, diuretic medications
- use of prescribed glucose-lowering/antidiabetic medication
- recent weight change in past 3 months,or does not habitually eat breakfast
- uncontrolled asthma, current fever, upper respiratory infections
- current intake of > 140g alcohol/week
Show all 11Show fewer
- current smokers of cigarettes/cigars/marijuana
- current intake of any illicit substance
- experience claustrophobia in confined spaces
- has donated blood within past 3-months
- unable to comprehend study protocol
Trial locations and contacts
1 site in 1 country.
About this study
Obesity is a serious medical condition, the adverse consequences of which include increased risk of cardiovascular disease, diabetes mellitus, reduced fertility and cancer. The economic cost of obesity was placed at $58 billion dollars in Australia in 2008. Studies in mice and non-human primates have shown that moderate caloric restriction (CR) increases lifespan and reduces the incidence of cardiovascular disease, cancer, and type 2 diabetes. Reduced risk of chronic diseases is also observed in humans following CR. However, daily CR is difficult to maintain long term, since the body defends against weight loss by inducing "metabolic adaptation" and altering the hormonal appetite response. An emerging number of studies are examining the effects of limiting food intake to prescribed time periods per day, or every other day. Intermittent, or time restricted feeding describes a dieting approach where food is available ad libitum, however only for a limited period of time (i.e. 3-12 hours). This study will examine the effects of fasting for 15h/day and eating for 9-h per day on glycemic control and metabolic health. This study will build on the existing knowledge base in humans as to whether meal timing, rather than caloric restriction per se, is important to provide the stimulus required to improve metabolic health and reduce risk of chronic disease. Moreover, it will examine whether restricting feeding to later in the day is of lesser benefit to health.
Read the detailed description
The timing of meal intakes distributed across the wake cycle may play a role in body weight regulation and metabolic health in humans. However, only a limited number of studies have interrogated this in humans. Epidemiological evidence shows that individuals who report consuming more of their daily energy intake at the evening meal were more overweight, than those who reported consumed more of their energy intake before lunch. Similarly, eating lunch late in the day (after 15:00 hrs) was predictive of poorer weight loss during a 20-week dietary intervention study and individuals randomized to consume more calories at breakfast had greater weight loss versus those randomized to eat more calories at dinner after 12 weeks. Taken together these data suggest that consuming more calories in the morning may be beneficial for weight management.
Randomised controlled cross-over intervention, where lean individuals were instructed either to consume all of their calories required for weight maintenance over a 4 hour period from 1700-2100h, or as 3 meals/d for 8 weeks. Significant reductions in body weight and body fat mass, by 1.4 and 2.1 kg respectively, were noted when following the TRF protocol. Consumption of the evening meal was supervised within the laboratory, to ensure subjects consumed the entire meal. In light of evidence that rats switched from a nibbling diet to 1 meal/d increased gluconeogenesis and free fatty acid flux from fat depots, the authors postulated that the greater weight loss may be associated with changes in metabolism. Despite this small amount of weight loss, fasting blood glucose levels were increased, and TRF resulted in poorer glucose tolerance in response to an oral glucose tolerance test (OGTT). Thus, consuming a single, large "dinner" meal was detrimental for metabolic health, although no differences in insulinemia were noted. It is unclear whether responses may have differed if the food allowance was prescribed at breakfast or lunch times. Just one other study has performed a randomised controlled TRF protocol in humans. In this study, healthy, lean male subjects were allowed to eat ad libitum for 13h per day (6am-7pm) for 2 weeks. Participants reported eating significantly less on the TRF versus the control condition, and lost -0.4kg compared with a gain of +0.6kg in the control condition. Whilst this is a minor change in body weight, this pattern is not that atypical of modern eating patterns, and further restriction of eating times, and assessment of obese individuals under these conditions is warranted. The metabolic health impacts were not reported in that study.
Several studies in animals have shown that, when fed in the "wrong" phase (i.e. eating when the animal would normally rest) the mice become obese, despite similar energy intake and expenditure, suggesting that the timing of food intake is important in driving the obese phenotype. Moreover, when high-fat energy intake is restricted to the active phase, the animals become obese, but do not develop the metabolic sequelae that are observed when the same foods are provided in the inactive phase. In humans, shift workers are at higher risks of metabolic disorders, including obesity and type 2 diabetes, possibly as a result of clock desynchronization. Alternatively, this may be the result of mis-timing of meals. For example, epidemiological evidence suggests that a shift toward consuming more calories at night is more likely to result in being overweight when compared with breakfast eaters, while eating a greater proportion of calories at the dinner meal is associated with a higher overall intake and an increased risk for obesity, metabolic syndrome and non-alcoholic fatty liver disease. When 10 healthy adults were subjected to a 28 hour "day" during which they consumed 4 isocaloric meals, the resulting circadian misalignment was associated with increased blood glucose, even in the presence of increased insulin. Moreover, in 3 of the subjects, a postprandial glucose response was observed that would suggest a pre-diabetic state. Under these circumstances, it appears that consuming calories at "night" in humans may have deleterious effects on health, and suggests that meal timing may play a key role in mitigating the metabolic impairment that occurs when the circadian rhythm is disrupted. To further confuse the matter, among breakfast skippers, a higher eating frequency (i.e. ≥ 4 eating occasions per day) has been shown to be associated with a higher risk for type 2 diabetes, compared with breakfast eaters who consumed 1-3 meals per day. In light of this evidence, and the apparent beneficial effects of TRF on metabolic health, the importance of the morning meal and its synchronisation with circadian rhythms is unclear.
Screening (S) - Participants will attend the South Australian Health and Medical Research Institute (SAHMRI) and have the research protocol explained to them in detail. Informed consent to participate in the study, including a verbal indication that they understand the general study protocol and requirements is then obtained. Participants will be assessed by a screening questionnaire for diet, medical, and exercise history to determine their eligibility according to the above criteria. Routine clinical checks are then performed (weight, height, waist circumference, blood pressure). If subjects meet eligibility criteria, they will be invited to take part in the study. Participants will have a dual energy x-ray absorptiometry scan and be fitted with a continuous glucose monitor for one week. During this time, participants will also wear an accelerometer and complete diet diaries to complete a baseline assessment of meal intake pattern. Participants will then be randomly assigned to undergo one of two study arms (TRF-b and TRF-d) for one week each. Conditions are separated by a 2-week washout period, during which participants will be encouraged to maintain their usual dietary pattern and physical activity levels.
Metabolic Testing (D0, D7) during each study condition: Participants arrive at 0700 following an overnight fast. Weight and blood pressure is measured following a seated 10 min rest. A 20 G cannula is inserted into an antecubital vein. A fasting blood sample is drawn for lipids, cytokines and glucoregulatory hormones. Resting metabolic rate and whole body nutrient oxidation is measured via indirect calorimetry. A second fasting blood sample is taken immediately prior to a standard test meal at 0800am or 1200pm, depending on study condition and gastric emptying, postprandial glucoregulatory and gut hormone response to re-feeding will be tested for 3 hours. At the first metabolic visit of each study condition, participants will be fitted with the continuous glucose monitor (CGM), and follow their assigned TRF protocol and assessments by CGM will continue for 7 days, before returning for the D7 metabolic visit. Diet records will be taken and accelerometers worn on the upper arm for each period during the study.
- Conditions
- Type 2 Diabetes, Insulin Resistance
- Being tested
- Lifestyle intervention B, Lifestyle Intervention D
- Medical subject headings
- Diabetes Mellitus, Type 2, Insulin Resistance
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Lifestyle intervention BBehavioural
Time limiting feeding from 8-5pm (TRFb)
Lifestyle Intervention DBehavioural
Time limiting feeding (12-9pm)
| Study group | Role | What they receive |
|---|---|---|
| TRF-b | Experimental | Participants are instructed to eat between 8am-5pm Receives: Behavioral: Lifestyle intervention B |
| TRF-d | Experimental | Participants are instructed to eat only between 12-9pm Receives: Behavioral: Lifestyle Intervention D |
| Baseline | No intervention | No lifestyle instruction given |
What is being measured
The primary outcome is the main question the study is designed to answer.
Postprandial glucose response to meal test
Measured: 3-hours
Secondary outcomes (3)
Postprandial insulin response to test meal
Measured: 3 hours
Post-prandial gut hormone response to test meal
Measured: 3 hours
Glycaemic response over 1 week by continuous glucose monitoring
Measured: 1-week
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted17 Dec 2015 (estimated)
- Study startJan 2016
- Primary completion30 Oct 2016
- Study completion30 Jul 2018
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (2)Papers the sponsor has linked to this study.
- Other trials for Type 2 DiabetesStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- None (open label)
- Enrolment
- 15 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of Adelaide
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, A/Prof Leonie Heilbronn, University of Adelaide
- Investigators
- Leonie Heilbronn, PhD, Principal investigator, The University of Adelaide
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02633722
- Sponsor's protocol ID
- UAdelaide
- Status last verified
- Oct 2018
- First submitted
- 15 Dec 2015
- Last updated
- 11 Oct 2018
- Results posted
- No
- Data monitoring committee
- No
- Individual data sharing
- Undecided
Publications
Allaf M, Elghazaly H, Mohamed OG, Fareen MFK, Zaman S, Salmasi AM, Tsilidis K, Dehghan A. Intermittent fasting for the prevention of cardiovascular disease. Cochrane Database Syst Rev. 2021 Jan 29;1(1):CD013496. doi: 10.1002/14651858.CD013496.pub2.
PubMed 33512717Hutchison AT, Regmi P, Manoogian ENC, Fleischer JG, Wittert GA, Panda S, Heilbronn LK. Time-Restricted Feeding Improves Glucose Tolerance in Men at Risk for Type 2 Diabetes: A Randomized Crossover Trial. Obesity (Silver Spring). 2019 May;27(5):724-732. doi: 10.1002/oby.22449. Epub 2019 Apr 19.
PubMed 31002478
Study at a glance
From the registry record, last updated by the sponsor on 11 Oct 2018. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Intermittent Fasting for Metabolic Health, Does Meal Timing Matter?
- ClinicalTrials.gov ID
- NCT02633722
- Acronym / sponsor ID
- UAdelaide
- Conditions
- Type 2 Diabetes, Insulin Resistance
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 15 participants (actual)
- Lead sponsor
- University of AdelaideUniversity, hospital or other
- Study start
- Jan 2016
- Primary completion
- 30 Oct 2016 (actual)
- Study completion
- 30 Jul 2018 (actual)
- First posted
- 17 Dec 2015 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Obesity is a serious medical condition, the adverse consequences of which include increased risk of cardiovascular disease, diabetes mellitus, reduced fertility and cancer. The economic cost of obesity was placed at $58 billion dollars in Australia in 2008. Studies in mice and non-human primates have shown that moderate caloric restriction (CR) increases lifespan and reduces the incidence of cardiovascular disease, cancer, and type 2 diabetes. Reduced risk of chronic diseases is also observed in humans following CR. However, daily CR is difficult to maintain long term, since the body defends against weight loss by inducing "metabolic adaptation" and altering the hormonal appetite response. An emerging number of studies are examining the effects of limiting food intake to prescribed time periods per day, or every other day. Intermittent, or time restricted feeding describes a dieting approach where food is available ad libitum, however only for a limited period of time (i.e. 3-12 hours). This study will examine the effects of fasting for 15h/day and eating for 9-h per day on glycemic control and metabolic health. This study will build on the existing knowledge base in humans as to whether meal timing, rather than caloric restriction per se, is important to provide the stimulus required to improve metabolic health and reduce risk of chronic disease. Moreover, it will examine whether restricting feeding to later in the day is of lesser benefit to health.
Detailed description
The timing of meal intakes distributed across the wake cycle may play a role in body weight regulation and metabolic health in humans. However, only a limited number of studies have interrogated this in humans. Epidemiological evidence shows that individuals who report consuming more of their daily energy intake at the evening meal were more overweight, than those who reported consumed more of their energy intake before lunch. Similarly, eating lunch late in the day (after 15:00 hrs) was predictive of poorer weight loss during a 20-week dietary intervention study and individuals randomized to consume more calories at breakfast had greater weight loss versus those randomized to eat more calories at dinner after 12 weeks. Taken together these data suggest that consuming more calories in the morning may be beneficial for weight management.
Randomised controlled cross-over intervention, where lean individuals were instructed either to consume all of their calories required for weight maintenance over a 4 hour period from 1700-2100h, or as 3 meals/d for 8 weeks. Significant reductions in body weight and body fat mass, by 1.4 and 2.1 kg respectively, were noted when following the TRF protocol. Consumption of the evening meal was supervised within the laboratory, to ensure subjects consumed the entire meal. In light of evidence that rats switched from a nibbling diet to 1 meal/d increased gluconeogenesis and free fatty acid flux from fat depots, the authors postulated that the greater weight loss may be associated with changes in metabolism. Despite this small amount of weight loss, fasting blood glucose levels were increased, and TRF resulted in poorer glucose tolerance in response to an oral glucose tolerance test (OGTT). Thus, consuming a single, large "dinner" meal was detrimental for metabolic health, although no differences in insulinemia were noted. It is unclear whether responses may have differed if the food allowance was prescribed at breakfast or lunch times. Just one other study has performed a randomised controlled TRF protocol in humans. In this study, healthy, lean male subjects were allowed to eat ad libitum for 13h per day (6am-7pm) for 2 weeks. Participants reported eating significantly less on the TRF versus the control condition, and lost -0.4kg compared with a gain of +0.6kg in the control condition. Whilst this is a minor change in body weight, this pattern is not that atypical of modern eating patterns, and further restriction of eating times, and assessment of obese individuals under these conditions is warranted. The metabolic health impacts were not reported in that study.
Several studies in animals have shown that, when fed in the "wrong" phase (i.e. eating when the animal would normally rest) the mice become obese, despite similar energy intake and expenditure, suggesting that the timing of food intake is important in driving the obese phenotype. Moreover, when high-fat energy intake is restricted to the active phase, the animals become obese, but do not develop the metabolic sequelae that are observed when the same foods are provided in the inactive phase. In humans, shift workers are at higher risks of metabolic disorders, including obesity and type 2 diabetes, possibly as a result of clock desynchronization. Alternatively, this may be the result of mis-timing of meals. For example, epidemiological evidence suggests that a shift toward consuming more calories at night is more likely to result in being overweight when compared with breakfast eaters, while eating a greater proportion of calories at the dinner meal is associated with a higher overall intake and an increased risk for obesity, metabolic syndrome and non-alcoholic fatty liver disease. When 10 healthy adults were subjected to a 28 hour "day" during which they consumed 4 isocaloric meals, the resulting circadian misalignment was associated with increased blood glucose, even in the presence of increased insulin. Moreover, in 3 of the subjects, a postprandial glucose response was observed that would suggest a pre-diabetic state. Under these circumstances, it appears that consuming calories at "night" in humans may have deleterious effects on health, and suggests that meal timing may play a key role in mitigating the metabolic impairment that occurs when the circadian rhythm is disrupted. To further confuse the matter, among breakfast skippers, a higher eating frequency (i.e. ≥ 4 eating occasions per day) has been shown to be associated with a higher risk for type 2 diabetes, compared with breakfast eaters who consumed 1-3 meals per day. In light of this evidence, and the apparent beneficial effects of TRF on metabolic health, the importance of the morning meal and its synchronisation with circadian rhythms is unclear.
Screening (S) - Participants will attend the South Australian Health and Medical Research Institute (SAHMRI) and have the research protocol explained to them in detail. Informed consent to participate in the study, including a verbal indication that they understand the general study protocol and requirements is then obtained. Participants will be assessed by a screening questionnaire for diet, medical, and exercise history to determine their eligibility according to the above criteria. Routine clinical checks are then performed (weight, height, waist circumference, blood pressure). If subjects meet eligibility criteria, they will be invited to take part in the study. Participants will have a dual energy x-ray absorptiometry scan and be fitted with a continuous glucose monitor for one week. During this time, participants will also wear an accelerometer and complete diet diaries to complete a baseline assessment of meal intake pattern. Participants will then be randomly assigned to undergo one of two study arms (TRF-b and TRF-d) for one week each. Conditions are separated by a 2-week washout period, during which participants will be encouraged to maintain their usual dietary pattern and physical activity levels.
Metabolic Testing (D0, D7) during each study condition: Participants arrive at 0700 following an overnight fast. Weight and blood pressure is measured following a seated 10 min rest. A 20 G cannula is inserted into an antecubital vein. A fasting blood sample is drawn for lipids, cytokines and glucoregulatory hormones. Resting metabolic rate and whole body nutrient oxidation is measured via indirect calorimetry. A second fasting blood sample is taken immediately prior to a standard test meal at 0800am or 1200pm, depending on study condition and gastric emptying, postprandial glucoregulatory and gut hormone response to re-feeding will be tested for 3 hours. At the first metabolic visit of each study condition, participants will be fitted with the continuous glucose monitor (CGM), and follow their assigned TRF protocol and assessments by CGM will continue for 7 days, before returning for the D7 metabolic visit. Diet records will be taken and accelerometers worn on the upper arm for each period during the study.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- None (open label)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| TRF-b | Experimental | Behavioral: Lifestyle intervention BParticipants are instructed to eat between 8am-5pm |
| TRF-d | Experimental | Behavioral: Lifestyle Intervention DParticipants are instructed to eat only between 12-9pm |
| Baseline | No intervention | –No lifestyle instruction given |
Who may qualify
- Ages
- 30 to 70 years
- Sex
- Male only
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (2 listed)
- Waist circumference >102cm
- BMI >30 kg/m2
Key exclusion criteria (11 listed)
- Personal history of cardiovascular disease, diabetes, eating disorders
- use of medications which may affect energy metabolism, gastrointestinal function, body weight or appetite (e.g. domperidone and cisapride, anticholinergic drugs, androgenic medications, metoclopramide, orlistat, diuretic medications
- use of prescribed glucose-lowering/antidiabetic medication
- recent weight change in past 3 months,or does not habitually eat breakfast
- uncontrolled asthma, current fever, upper respiratory infections
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Lifestyle intervention BTime limiting feeding from 8-5pm (TRFb) | Behavioural | TRF-b |
| Lifestyle Intervention DTime limiting feeding (12-9pm) | Behavioural | TRF-d |
Primary outcome
Postprandial glucose response to meal test
Time frame: 3-hours
3 secondary outcomes
Postprandial insulin response to test meal
Time frame: 3 hours
Post-prandial gut hormone response to test meal
Time frame: 3 hours
Glycaemic response over 1 week by continuous glucose monitoring
Time frame: 1-week
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 11 Oct 2018.
- Derived from this study: PubMed 33512717Allaf M, Elghazaly H, Mohamed OG, Fareen MFK, Zaman S, Salmasi AM, Tsilidis K, Dehghan A. Intermittent fasting for the prevention of cardiovascular disease. Cochrane Database Syst Rev. 2021 Jan 29;1(1):CD013496. doi: 10.1002/14651858.CD013496.pub2.
- Derived from this study: PubMed 31002478Hutchison AT, Regmi P, Manoogian ENC, Fleischer JG, Wittert GA, Panda S, Heilbronn LK. Time-Restricted Feeding Improves Glucose Tolerance in Men at Risk for Type 2 Diabetes: A Randomized Crossover Trial. Obesity (Silver Spring). 2019 May;27(5):724-732. doi: 10.1002/oby.22449. Epub 2019 Apr 19.
- Individual participant dataSharing planned: Undecided
Related trials for Type 2 Diabetes
Not yet recruitingPhase 3
Efficacy and Safety of Once-Weekly SHR-3167 Compared With Once-Daily Insulin Glargine in Adults With Insulin-Naive Type 2 Diabetes
Type 2 Diabetes
Active, not recruiting
Digital Reinforcement of Motivational Interviewing Micro-Skills Among Primary Care Healthcare Professionals
Hypertension (Without Type 2 Diabetes Mellitus)
Recruiting
Investigating Vascular Properties of HEMI and SPG Signals in Individuals With or at Risk for Chronic Kidney Disease
Chronic Kidney Disease, Hypertension (HTN)
Not yet recruitingPhase 3
A Study to Evaluate the Effectiveness and Safety of the Drug AZD6234 for Managing Weight in Adults Who Are Obese or Overweight. These Participants May or May Not Also Have Type 2 Diabetes
Obesity, Overweight
Not yet recruiting
Impact of Endoscopic Sleeve Gastroplasty (ESG) in Obese Adults With Type 2 Diabetes (T2D)
Type 2 Diabetes Mellitus (T2D), Obesity (BMI>30)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Leonie Heilbronn, PhD principal investigator
The University of Adelaide
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Lifestyle intervention B and Lifestyle Intervention D in people with Type 2 Diabetes and Insulin Resistance, run by University of Adelaide at 1 site in Australia.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 11 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 11 Oct 2018. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Australia. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Postprandial glucose response to meal test (time frame: 3-hours). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT02633722, which also lists 2 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 11 Oct 2018.